Insider Selling: Humanigen, Inc. (NASDAQ:HGEN) Insider Sells 14,700 Shares of Stock

Humanigen, Inc. (NASDAQ:HGEN) insider Edward P. Jordan sold 14,700 shares of the firm’s stock in a transaction that occurred on Tuesday, June 8th. The shares were sold at an average price of $20.08, for a total transaction of $295,176.00. Following the transaction, the insider now directly owns 14,700 shares in the company, valued at approximately $295,176. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Shares of Humanigen stock opened at $21.07 on Friday. The business has a fifty day moving average of $18.12. The firm has a market capitalization of $1.24 billion, a P/E ratio of -6.22 and a beta of -2.39. The company has a debt-to-equity ratio of 1.44, a quick ratio of 1.85 and a current ratio of 1.85. Humanigen, Inc. has a 1 year low of $7.50 and a 1 year high of $33.95.

Humanigen (NASDAQ:HGEN) last announced its quarterly earnings data on Thursday, May 13th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.61). On average, analysts anticipate that Humanigen, Inc. will post 3.45 earnings per share for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the business. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in Humanigen during the first quarter worth $29,000. Pacer Advisors Inc. acquired a new stake in Humanigen during the first quarter worth $93,000. Royal Bank of Canada boosted its stake in Humanigen by 21.1% during the first quarter. Royal Bank of Canada now owns 6,900 shares of the company’s stock worth $132,000 after buying an additional 1,200 shares in the last quarter. Winslow Evans & Crocker Inc. acquired a new stake in Humanigen during the fourth quarter worth $144,000. Finally, E Fund Management Co. Ltd. acquired a new stake in Humanigen during the first quarter worth $165,000. Hedge funds and other institutional investors own 38.56% of the company’s stock.

Several equities analysts recently weighed in on HGEN shares. JPMorgan Chase & Co. started coverage on shares of Humanigen in a research report on Tuesday, February 23rd. They set a “neutral” rating and a $21.00 price objective on the stock. Zacks Investment Research lowered shares of Humanigen from a “hold” rating to a “sell” rating in a research report on Wednesday, May 19th. Roth Capital raised their price objective on shares of Humanigen from $35.00 to $37.00 and gave the company a “buy” rating in a research report on Wednesday, May 5th. Oppenheimer initiated coverage on shares of Humanigen in a research report on Thursday, May 6th. They set an “outperform” rating and a $30.00 price objective on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $36.00 price target (up previously from $34.00) on shares of Humanigen in a report on Monday, April 19th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. Humanigen currently has an average rating of “Buy” and a consensus target price of $30.14.

About Humanigen

Humanigen, Inc, a clinical stage biopharmaceutical company, develops a portfolio of immuno-oncology and immunology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which is in Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory B-cell lymphoma, as well as that has completed Phase I clinical trial in patients with chronic myelomonocytic leukemia.

Recommended Story: Return on Equity (ROE)

Insider Buying and Selling by Quarter for Humanigen (NASDAQ:HGEN)

Receive News & Ratings for Humanigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humanigen and related companies with MarketBeat.com's FREE daily email newsletter.